SUPPLEMENT 3. Treatment responses and remission rates on TNF–inhibitors used as the patients’ first bDMARD either as monotherapy or in concert with methotrexate or other csDMARDs within 6 months of treatment onset.

**EULAR response at 6 months**
- Monotherapy: 59% Moderate Response, 69% Good Response, 57% Total Response
- MTX: 38% Moderate Response, 46% Good Response, 53% Total Response
- Other csDMARDs: 20% Moderate Response, 23% Good Response, 10% Total Response

**EULAR (lundex–adjusted) response at 6 months**
- Monotherapy: 42% Moderate Response, 45% Good Response, 42% Total Response
- MTX: 27% Moderate Response, 30% Good Response, 30% Total Response
- Other csDMARDs: 10% Moderate Response, 14% Good Response, 17% Total Response

**ACR response at 6 months**
- Monotherapy: 51% ACR 20 response, 48% ACR 50 response, 57% ACR 70 response
- MTX: 38% ACR 20 response, 33% ACR 50 response, 31% ACR 70 response
- Other csDMARDs: 20% ACR 20 response, 23% ACR 50 response, 10% ACR 70 response

**ACR (lundex–adjusted) response at 6 months**
- Monotherapy: 36% ACR 20 response, 32% ACR 50 response, 31% ACR 70 response
- MTX: 27% ACR 20 response, 22% ACR 50 response, 17% ACR 70 response
- Other csDMARDs: 14% ACR 20 response, 15% ACR 50 response, 5.7% ACR 70 response

**DAS28 remission at 6 months**
- Monotherapy: 68% Remission
- MTX: 68% Remission
- Other csDMARDs: 67% Remission

**DAS28 (lundex–adjusted) remission at 6 months**
- Monotherapy: 48% Remission
- MTX: 45% Remission
- Other csDMARDs: 37% Remission